SUMMARY
Cytochrome P450 monooxygenases (P450s) have enormous potential in production of oxychemicals, due to their unparalleled regioand stereoselectivity. The Bacillus megaterium P450 BM3 enzyme is a key model system, with several mutants (many distant from the active site) reported to alter substrate selectivity. It has the highest reported monooxygenase activity of the P450 enzymes and this catalytic efficiency has inspired protein engineering to enable its exploitation for biotechnologically relevant oxidations with structurally diverse substrates. However, a structural rationale is lacking to explain how these mutations have such effects in absence of direct change to the active site architecture. Here we provide the first crystal structures of BM3 mutants in complex with a human drug substrate: the proton pump inhibitor omeprazole. Supported by solution data, these structures reveal how mutation alters the conformational landscape and decreases the free energy barrier for transition to the substrate-bound state. Our data point to the importance of such "gatekeeper" mutations in enabling major changes in substrate recognition. We further demonstrate that these mutants catalyze the same 5-hydroxylation reaction as performed by human CYP2C19, the major human omeprazole metabolizing P450 enzyme.
The cytochrome P450 monooxygenases (P450s) are hemoproteins that catalyse a huge range of biochemical transformations, including key reactions involved in the biosynthesis of steroids, antibiotics and signaling lipids (1, 2) . Recent years have seen intensive efforts to exploit the P450s' ability to catalyze regio-and stereoselective oxidations of substrates in order to make biotechnologically useful products. Examples include the rational engineering of the Pseudomonas putida camphor hydroxylase P450cam (CYP101A1) for improved binding and oxidation of environmentally recalcitrant polychlorinated benzenes, and the use of directed evolution for the conversion of specificity of the Bacillus megaterium P450 BM3 (CYP102A1, BM3) from long chain fatty acids towards short chain hydrocarbons (3, 4) . BM3 has proven a particularly versatile and popular model system for use in engineering studies, benefiting from the fact that it is a natural fusion of a P450 to its mammalian-like diflavin reductase redox partner (enabling efficient electron transfer that underpins its high monooxygenase activity (5, 6) ), and that the structure of its P450 domain and roles of many active site amino acids are well understood (7) (8) (9) (10) .
Recent work to diversify BM3's substrate selectivity and reactivity has produced variants that catalyze olefin cyclopropanation by carbene transfer and oxidation of e.g. testosterone, polycyclic aromatic hydrocarbons and pharmaceuticals (11) (12) (13) (14) . In the latter case, an aim is to engineer BM3 to generate high levels of metabolites typical of those formed by human P450s. Approaches to engineering BM3 have included directed evolution, chimeragenesis (with homologs from B. subtilis) and CASTing, as well as structure-led mutagenesis guided by X-ray crystal structures of BM3's P450 (heme) domain in substrate-free (SF), fatty acid-bound (SB) and various mutant forms (e.g. 7, 8, 15, 16) . Many studies identified common residues that help facilitate substrate diversification. These include Phe87, Ala82, Val78 and Arg47; the first three of which are internal residues, while Arg47 interacts with the fatty acid carboxylate at the protein surface (6, 10) . Phe87 interacts with the ω-end of fatty acids and prevents oxidation at this position. Phe87 mutations alter regioselectivity of fatty acid oxidation, with positions of hydroxylation of lauric acid moving from ω-1/ ω-2/ ω-3 (WT BM3) towards ω-5 in F87A/S/G mutants, and even further from the ω-position in a F87A/V78A double mutant (6, 17) . The F87A mutation also activated BM3 in hydroxylation of testosterone (12) .
While alterations that influence local structure in the BM3 active site cavity clearly have potential to alter binding position of fatty acids and to enable docking of novel substrates, other BM3 mutations were shown to have a more profound effects on the P450's conformational landscape (18, 19) . One of the more common activity-altering BM3 mutants (A82F) shows greatly enhanced affinity for fatty acid substrates. While the crystal structure of palmitate-bound A82F heme domain was solved in the SB-type conformation (20) , this did not provide a clear rationale for its much improved affinity for fatty acids. Also, despite several studies involving mutagenesis of BM3 to improve its capacity to oxidize human pharmaceuticals, there are no structural data to provide insight into how improved mutants enable binding of the new substrates, or to guide subsequent engineering to further enhance binding and desired activities.
In this study we characterize the structural and biochemical/catalytic properties of the A82F, F87V and F87V/A82F mutants of BM3, demonstrating a novel activity in oxidation of the widely used gastric proton pump inhibitor (PPI) omeprazole (Figure 1) , and generating products typical of those formed by the major human metabolizing P450 enzyme CYP2C19 (21) . Structural data for substrate-free and omeprazole-bound forms of the A82F and double mutant BM3 heme domains provide clear evidence for the "gatekeeper" nature of the A82F mutation, which produces a major structural rearrangement of the BM3 heme domain that leads to novel molecular selectivity. These first structural data for BM3 in complex with a human drug substrate highlight how combinations of conformational effector mutations (e.g. A82F) with secondary mutations that make local structural changes to alter binding in the heme vicinity (e.g. F87A/V) can be combined to cause dramatic changes in P450 substrate selectivity for biotechnological applications.
Experimental Procedures

Generation, expression and purification of WT and mutant P450 BM3 proteins
Mutants of the intact P450 BM3 and its heme domain were generated by oligonucleotidedirected mutagenesis. Intact WT P450 BM3 in pET15b was used for mutagenesis to create A82F, F87V and F87V/A82F (DM) mutants. Mutations (positions underlined) were generated using the QuikChange Lightning site directed mutagenesis kit (Stratagene-Agilent UK). Primers  used  were  A82F  5'-CTTAAATTTGTACGTGATTTTTTCGGAGA  CGGGTTA-3',  F87V  5'-TTGCAGGAGACGGGTTAGTTACAAGCTG  GACGCATG-3', F87V in A82F background 5'-TTTTCGGAGACGGGTTAGTTACAAGCTG  GACGCATG-3'  (and  their  reverse  complements) . These intact BM3 enzymes were expressed as N-terminal hexahistidine tagged enzymes either using the pET15b (F87V, DM) constructs directly, or following cloning of the WT and A82F genes into pET14b using NdeI/BamHI sites. WT and mutant heme domain genes were generated using the relevant pET14b/15b constructs. To generate the heme domain constructs, a stop codon pair (underlined) was introduced after residue 473 by PCR using the same mutagenesis kit, and with primers StopF 5'-CAGTCTGCTAAAAAAGTACGCAAATAGT AGGAAAACGCTCATAATACGCCGCTG-3' and StopR 5'-CAGCGGCGTATTATGAGCGTTTTCCTACT ATTTGCGTACTTTTTTAGCAGACTG-3'. The heme domain genes (amino acids 1-473) were transferred as NdeI/BamHI fragments to pET20b to enable heme domain production in absence of a N-terminal His-tag for improved crystallization. Genes were sequenced to ensure presence of desired mutation(s) and absence of other mutations. The WT and A82F intact BM3, and the WT and all mutant P450 BM3 heme domain proteins were expressed in BL21-Gold (DE3) E. coli cells (Stratagene-Agilent UK) using TB medium with cell growth at 37 °C and with agitation at 200 RPM in an orbital incubator. The F87V and DM intact BM3 proteins were grown in autoinduction TB medium (Melford Ltd, Ipswich UK). Typically, 4 L bacterial cultures were used for protein production with cell growth for 24-36 hours.
Following cell growth, bacterial cells were recovered by centrifugation at 4 °C (6000 g, 10 min) and resuspended in ice-cold buffer B (50 mM KPi, 250 mM NaCl, 10% (v/v) glycerol, pH 7.0) containing protease inhibitors (EDTA Free Complete TM tablets, Roche, Germany). Protease inhibitors were maintained in all subsequent buffers used for protein purification. Cells were lysed by sonication on ice using a Bandelin Sonopuls sonicator (40% power, 50 pulses for 5 s with 25 s between pulses). The supernatant containing soluble intact BM3 and heme domain proteins was separated from cell debris by centrifugation (20,000 g, 40 min, 4 °C) and ammonium sulfate was added to 30% saturation on ice with slow stirring for ~4 h. Centrifugation (20,000 g, 40 min, 4 °C) was done to fractionate soluble BM3 and heme domain proteins from insoluble material. Intact BM3 WT and mutant proteins in the supernatant were purified using His-tag affinity by mixing with Ni-IDA resin (Qiagen, UK) overnight at 4 °C in buffer B with 5 mM imidazole, prior to elution with 200 mM imidazole in buffer B. Isolated proteins were dialyzed into buffer A (50 mM Tris, 1 mM EDTA, pH 7.2) and further purified by size exclusion chromatography using a Sephacryl S-200 column (GE Healthcare, 26 x 60 cm on an AKTA purifier system). BM3 fractions were checked for purity by SDS-PAGE, concentrated by ultrafiltration (Vivaspin, Vivaproducts, USA) and frozen in buffer A plus 50% glycerol at -80 °C). For the non-tagged BM3 heme domains, supernatants subsequent to the 30% ammonium sulfate fractionation were subjected to a second ammonium sulfate fractionation step at 60% salt saturation. The pellet was resuspended in buffer A and extensively dialyzed into the same buffer to desalt, prior to loading onto a Q-Sepharose anion exchange column (16 x 10 cm, on an AKTA) and eluting using a gradient of 0-500 mM KCl in buffer A. Heme domain-containing fractions were desalted by using a desalting column (GE Healthcare, 26 x 10 cm on an AKTA) into 25 mM KPi pH 7.0, and then loaded onto a hydroxyapatite column (Bio-Rad, USA, 16 x 11 cm) and eluted in a linear gradient of 25 mM -500 mM KPi, pH 7.0 (200 mL). Pure heme domain fractions were concentrated by ultrafiltration (Vivaspin) and used immediately for crystallography, or flash frozen in liquid nitrogen and stored at -80 °C. Due to the enhanced affinity for fatty acids in BM3 and heme domain proteins carrying the A82F mutation, all enzymes were passed through a Lipidex 1000 column (Perkin Elmer, UK) in 25 mM KPi, pH 7.0 to remove any fatty acid bound during purification, and prior to use for crystallization (heme domains), or for binding or turnover studies (heme domain and intact BM3 enzymes).
Quantification of P450 BM3 enzymes and determination of their substrate affinity and steady-state kinetic properties
Concentrations of the low-spin forms of the WT and mutant forms of intact P450 BM3 and its heme domain were determined using extinction coefficients of ε = 105 and 95 mM
, respectively, at the Soret maximum (418 or 419 nm), as described previously (6) . Thiolate coordination of the heme iron in all samples was established by formation of the Fe(II)CO complex at ~450 nm by bubbling of sodium dithionite-reduced WT and mutant BM3 and heme domain samples (ca 2-4 µM) with carbon monoxide gas, as described by Omura and Sato (22) . All samples showed near complete conversion to the P450 form, with negligible formation of an ~420 nm peak relating to the thiol-coordinated P420 form (23, 24) .
Dissociation constants (K d values) for binding of the substrates N-palmitoylglycine (NPG) and omeprazole (OMP) to WT and mutant BM3 heme domains were determined by UV-visible absorption titrations using ~1-4 µM protein in 100 mM KPi (pH 7.0) at 25 °C (assay buffer) in 1 cm pathlength quartz cuvettes, and as in our previous studies (6, 16, 25) . Spectra were recorded for substrate-free enzymes, and following addition of ligands during substrate titrations (typically 800-250 nm). Titrations were recorded until no further spectral changes were observed in the P450s. Difference spectra were generated by subtraction of the spectrum for ligand-free protein from spectra recorded after each addition of substrate. Maxima and minima in difference spectra were identified (using the same wavelength pair in each titration) and the overall absorbance changes ∆(A peak minus A trough ) were plotted versus [substrate]. Data were fitted using either a standard (Michaelis-Menten) hyperbolic function or (for tight binding substrates where the K d value is ≤ 5x the P450 concentration) by using the Morrison equation (as described previously) to determine K d values (26, 27) . UVVis spectroscopy was carried out on a Cary 50 UV-Vis spectrometer (Cary-Agilent, UK), with data analysis and fitting done using Origin Pro software (OriginLab, Massachusetts USA). 
Omeprazole and 5-OH omeprazole turnover and analysis by LC-MS
Turnover reactions for oxidation of OMP were carried out in deep well blocks at 37 °C with shaking for 30 min. Reaction mixtures contained purified WT or mutant (F87V, A82F or DM BM3) enzymes (0.1 µM), substrate (10 µM), NADPH regeneration system (glucose-6-phosphate, 7.76 mM; NADP + , 0.6 mM; and glucose-6-phosphate dehydrogenase, 0.75 U/ml) in turnover buffer (50 mM KPi, 5 mM CaCl 2 , pH 7.4) in a final volume of 500 µL. Following completion of the reaction, protein was precipitated by addition of an equal volume of acetonitrile (ACN) containing 1 µg/ml fluconazole by shaking the mixed samples at 800 rpm for 10 min. The precipitated protein was filtered through protein precipitation plates (Phenomenex, Macclesfield UK) into mass spectrometry vials (FluidX, Nether Alderley UK) and clarified by centrifugation (4000 g, 25 min, 10 o C). Analysis was carried out on a Thermo Exactive LC-MS with a CTC PAL auto sampler (Thermo Scientific, UK) with a Kinetex 2.6U XB -C18 100A column (Phenomenex). A gradient of 0.1 % formic acid to ACN was used to resolve products. Reaction of the DM BM3 enzyme with 5-OH OMP and subsequent product analysis was done in the same way as for the OMP turnovers.
Omeprazole turnover and analysis by NMR
Turnover reactions with OMP were carried out in a 100 mL flask at 37 °C with shaking of reagents at 100 rpm for 30 min. Reaction mixtures contained purified WT or mutant (F87V, A82F or DM intact BM3) enzymes (1 µM), substrate (100 µM), NADPH regeneration system (glucose-6-phosphate 7.76 mM, NADP + 0.6 mM, and glucose-6-phosphate dehydrogenase 0.75 U/ml) in 60 mL assay buffer (100 mM KPi, pH 7.0). Products were extracted using Strata-X SPE columns (Phenomenex), dried under vacuum and eluted in CDCl 3 . Analysis was carried out on a Bruker Avance 400 MHz NMR (Bruker, Coventry UK). Background scans were carried out with degassed assay buffer, saturated with OMP or NPG for the substrate-bound samples. Protein samples were prepared in assay buffer by extensive buffer exchange and dialysis. All samples were run using 20 µM protein and saturating substrate. Once two overlapping baseline scans were achieved, a degassed protein sample was run.
Crystallization of P450 BM3 heme domains and determination of protein structures
Crystallography was performed using the sitting drop method using a seeding protocol at 4 °C. Crystals obtained during initial screens for each mutant were used to create microcrystal screen stocks and consecutive screens (Molecular Dimensions) were made with drops that consisted of 150 nL of WT or mutant heme domain proteins (230 µM), 50 µL of seed stock and 200 nL well solution using a Mosquito liquid handling robot (TTP LabTech Ltd, Melbourn UK). For the OMP mutant heme domain complex structures, proteins were saturated with racemic OMP ligand prior to crystallization. Ligands were titrated into heme domain samples until no further change in heme iron spin-state (towards high-spin) was observed. Thereafter, samples were concentrated by ultrafiltration in the presence of saturating ligand. Micro seeding was also used to produce diffraction quality crystals. Crystals were obtained under a range of conditions and flashcooled in liquid nitrogen prior to data collection. The mother liquor was supplemented with 10% PEG 200 where an additional cryo-protectant was required. Data were collected at Diamond synchrotron beamlines and reduced and scaled using XDS (28) . Structures were solved by molecular replacement with previously solved BM3 heme domain structures (PDB 1JPZ) using PHASER (29) . Structures were refined using Refmac5 (29) and Coot (30) . PDB codes for the new heme domain structures are A82F: 4KF0; F87V/A82F (DM, imidazole-bound): 4KF2; A82F (OMP-bound): 4KEW; and DM (OMPbound): 4KEY.
Materials
Oligonucleotide primers were from Eurofins MWG Operon (Ebersberg, Germany). Omeprazole was from Cypex Ltd (Dundee, UK). 5-OH omeprazole was from Santa Cruz Biotechnology, Inc. (Dallas, USA). The bacterial growth medium (Terrific Broth, TB) was from Melford Ltd (Ipswich, UK). Unless otherwise stated, other chemicals were from SigmaAldrich and of the highest purity available.
Results
Characterization of omeprazole binding properties of BM3 mutants
Preceding studies identified Ala82 and Phe87 as important in controlling molecular selectivity and regioselectivity of BM3 substrate oxidation (16, 20, 31) . WT, F87V, A82F and the F87V/A82F double mutant (DM) forms of intact P450 BM3 and of its heme domain (residues 1-473) were expressed and purified as described in the Experimental Procedures. The BM3 ferric heme iron undergoes a shift from low-spin (LS) towards high-spin (HS) on binding substrates that displace its 6 th ligand (a water molecule), accompanied by a shift of Soret absorption maximum from ~418 nm to ~392 nm (32) . Binding of the substrate N-palmitoylglycine (NPG) was done for WT, F87V, A82F and the DM BM3 proteins. WT and all mutants bound NPG tightly, with K d values < 1 µM ( Table 1 ).
The A82F mutant has particularly high affinity for lipids and was purified from E. coli with fatty acid bound, as was the DM. Separation of the bound lipid by Lipidex chromatography was done prior to analysis. Binding studies with the PPI omeprazole (OMP) revealed no evidence for its association with WT BM3, but partial spinstate conversion was observed for F87V BM3, indicative of ability of the drug to access the active site (K d = 49 µM). Much tighter binding and more extensive HS heme accumulation was observed with both A82F and the DM (K d values = 1.67 and 0.21 µM, respectively), indicating that the mutations had synergistic effects in enhancing OMP affinity, with A82F having the major role ( Figure 2A , Table 1 ).
Steady-state kinetics of P450 BM3 mutants with omeprazole
Steady-state kinetic analysis was done for WT and each of the intact BM3 mutants by following NADPH oxidation on addition of various concentrations of NPG or OMP (24) . Table 1 ), but kinetics were substantially improved in all the mutants (e.g. 1500 min -1 for DM), and apparent OMP affinity for the DM was ~65-fold greater than for WT BM3 (K m values of 1.9 µM vs. 124 µM), resulting in a >400-fold improvement in catalytic efficiency (k cat /K m ratio) for the DM over WT BM3.
Oxidation of omeprazole by WT and mutant P450 BM3 enzymes
To validate novel omeprazole oxidase activity in mutant BM3 enzymes, in vitro turnover studies were done as described in detail in the Experimental Procedures, using LCMS and NMR to characterize products formed. WT BM3 exhibited very small amounts of oxidation of OMP (< 1% of the starting material), but the low amounts obtained precluded determination of position(s) of oxidation. However, each of the three mutants extensively oxidized the drug.
LC-MS revealed a 362.1162 amu species in all the mutant turnover reactions, corresponding to introduction of an oxygen atom into OMP (Figure 3) . A natural fragmentation of the OMP molecule occurs in the MS, with bond breakage between the sulfur and the methoxybenzimidazole moiety (Figure 1) . A +16 increase in mass of the larger fragment indicated that oxidation occurs on this portion of OMP. Further fragmentation of the oxidized molecule showed that the position of oxidation was likely on one of the two 4-methoxy-3,5-dimethylpyridin-2-yl (hereafter termed pyridinyl) methyl groups ( Figure 3 ). This was confirmed by 1 H NMR spectroscopy after larger scale reactions of mutant enzymes with OMP, and the absolute position of oxidation was confirmed using 2D NMR -showing that a specific hydroxylation occurred on the pyridinyl 5-methyl group (forming 5-OH OMP) (Supplemental Data Figures S1-S4 ). This same reaction is also catalyzed by CYP2C19, the major metabolizing P450 for OMP and other PPIs in humans (33) .
In OMP turnovers done over 30 min, the total oxidative turnover of OMP was greatest for the DM (~55%), followed by the F87V (~50%) and the A82F (~20%) mutants ( Figure 2B ). LCMS demonstrates the formation of considerable amount of a +32 species (~10%) in the case of the DM, which was shown to be the carboxylic acid product at the pyridinyl 5-methyl group (5-COOH OMP), resulting from further P450-mediated oxidation at the same position. By comparing the amount of NADPH oxidized with the quantity of OMP oxidized over the first two minutes of reactions, enzymatic coupling was estimated as 68% for both the A82F and DM BM3 enzymes, and 39% for the F87V variant. These data suggest that structural changes induced by the A82F mutation are the major determinant of the productive binding mode for OMP, and thus the coupling efficiency. (DM), but NADPH oxidation was not stimulated significantly above background in the WT BM3 (Table 2) . A time course for the oxidation of OMP into 5-OH OMP and 5-COOH OMP products by the BM3 DM enzyme is shown in Figure 5 . Approximately 30% of the 5-OH OMP is further oxidized to 5-COOH OMP by the DM BM3 over 30 minutes.
Structural analysis of omeprazole-binding P450 BM3 mutants
The effect of the F87V mutation in enabling OMP binding may be explained using available structural information for the BM3 heme domain, as space vacated by the F87V substitution directly above the heme plane is likely to allow binding of the bulky substrate (6) . The marked effects of the A82F mutation, however, are not intuitive given the peripheral position of A82 to the substrate binding pocket.
To gain detailed understanding of the effects of the A82F mutation in promoting OMP binding, both the A82F and the F87V/A82F double mutant were co-crystallized with OMP, and structures solved by molecular replacement using the NPG-bound heme domain structure (PDB code 1JPZ) (34) . Crystal structure PDB codes are 4KEW for the OMP-bound A82F heme domain, and 4KEY for DM heme domain. In both cases, the global conformation of the heme domain is remarkably similar to previously determined fatty-acid bound structures (0.3 Å over 450 Cα atoms) (8,34) ( Figure 6A , Table 3 ).
The PPI ligand is clearly identified from the electron density occupying the substrate binding channel for the OMP complex. In both cases, electron density corresponding to the oxygen atom of the central sulfinyl groups is weak, and it is possible both stereoisomers are present from the racemic mixture. OMP was also shown to be relatively labile, with loss of oxygen from the sulfone noted in aqueous solution (35) ( Figure  6B ). We thus modeled OMP without the sulfone oxygen. The pyridinyl moiety is placed in a near-perpendicular orientation directly above the heme plane. The close distance to the heme of the OMP 5-methyl group, in particular, leads to displacement of the water 6 th ligand, and this conformation is consistent with the observed 5-OH OMP product. The heme iron to OMP 5-methyl group distances are 3.9 Å and 4.1 Å in the A82F and DM heme domains, respectively. A single direct hydrogen bond is made between the backbone carbonyl of Leu437 and one of the methoxybenzimidazole nitrogens. Water molecules are present in close proximity to the other OMP polar groups, and these also mediate a network of hydrogen bonds between protein and ligand. Specific interactions are made via a bridging water molecule between (i) the Ala74 backbone nitrogen and the methoxy oxygen of the methoxybenzimidazole; and (ii) the hydroxyl oxygen of Ser72 and the second methoxybenzimidazole nitrogen. While there are no substantial differences in the orientation of the methoxybenzimidazole group for both mutants, close contacts between Phe87 and the pyridinyl moiety in the A82F mutant structure leads to small reorientation of the substrate in comparison to the DM structure. In the latter, the reduced bulk of the Val87 appears to provide sufficient space for the substrate to adopt a less strained conformation. This likely explains the difference in affinity observed between the A82F and DM mutants. Other protein-OMP interactions in the A82F and DM complex structures involve hydrophobic interactions between residues near both the pyridinyl (e.g. Thr438, Ile263, Ala328) and methoxybenzimidazole (e.g. Val26, Leu188) ends of the OMP substrate ( Figure 7) .
A clear rationale for the marked difference in OMP affinity between A82F containing mutants and the WT BM3 is not provided by the mutant-OMP structures. Figure 8A shows the active sites in detail for the overlaid A82F OMP-bound BM3 heme domain and the NPG-bound WT heme domain. The additional bulk of the Phe82 side chain only interacts edge-on with the pyridinyl moiety of OMP, and the only significant change in the positions of nearby key residues occurs for Phe87. The Phe87 side chain is seen in different conformations in the A82F/OMP structure, compared to the WT BM3/NPG heme domain. Figure 8B shows an alternative view of the active site for the DM/OMP-bound heme domain and the WT/NPG-bound P450, looking along the I helix, with the F/G helices highlighted. This reinforces the strong structural similarity between the WT and DM mutant substrate-bound structures. All these structures occupy the substrate-bound (SB) conformation. However, the ligand-free A82F and DM heme domains also have the SB conformation ( Figure 6A ) However, the WT BM3 heme domain occupies a distinct conformation when substrate-free (SF), and thus the A82F mutation is key to shifting the equilibrium between SF and SB conformations. Previous studies also showed that the structural state of the heme domain can be significantly affected by single mutations at key positions (36) .
We also determined the crystal structures of the ligand-free and imidazole-bound A82F (PDB code 4KF0) and DM (4KF2) heme domains. In the latter case, imidazole present in the crystallization buffer ligated to the heme iron. These structures share a similar conformation that is again distinct from previously observed WT BM3 heme domain SF structures ( Figure  6A, Figure 9 ). These data again point to the A82F substitution producing dramatic changes in the structure and behavior of ligand-free A82F-containing mutants. The most significant changes occur in the positioning of the FG helices, which adopt a conformation that places the FG-loop further away from the protein core, leading to increased mobility. This altered position is a consequence of a reorganization of the hydrophobic contact between the FG-helices and the I-helix. In the WT SF conformation, the N-terminal region of the I-helix adopts a slightly different orientation compared to the SB conformation. In the case of the A82F-containing mutants, this motion leads to a close contact between Ile263 and Phe82 ( Figure 9 ). This results in a minor reorientation of the Ihelix and the Ile263 side chain, which directly affects the position of the G-helix residue Met177. The repositioning of the G-helix is accompanied by reorientation of hydrophobic residues on the B-and F-helices.
While the F87V mutant enables binding of OMP detectable by heme absorbance shift, the K d for OMP binding to F87V BM3 heme domain is ~30-fold and 230-fold weaker than that observed for the A82F and DM heme domains, respectively. The improved ligand binding properties of the A82F mutants can be understood in view of the large changes introduced by the A82F mutation in the ligandfree, but not ligand-bound, structures. The shift in the BM3 conformational equilibrium from SF to SB (as induced by ligand binding) is dependent on the free energy difference between both conformations, and the free energy associated with ligand binding. The A82F-containing mutant crystal structures suggest that the mutation leads to a substantially altered free energy difference between both conformations. The fact OMP only appears to bind with measurable affinity to A82F-containing mutants suggests that the A82F mutation destabilizes the substrate-free conformation.
To confirm this hypothesis, we performed DSC analysis of the substrate-free and OMP-bound forms of WT and all mutant heme domains; and compared data with NPG-bound forms. The results showed that both F87V and A82F mutations diminished thermal stability of the BM3 heme domain. The WT heme domain has two unfolding transitions (T m values) at 65.7 °C (T m 1, major) and 59.0 °C (T m 2, minor). The T m values are not altered significantly by OMP, but NPG stabilizes the P450 (T m 1 = 70.4 °C). Consistent with our model, the A82F T m 's are 59.7 °C and 49.7 °C -substantially lower than WT BM3. F87V was also destabilized, albeit to a lesser extent, with the minor transition no longer seen (T m 1 = 61.3 °C). The DM showed greatest destabilization (T m 's = 50.9 °C and 58.0 °C). Binding of OMP to A82F-containing mutants resulted in single unfolding transitions, with negligible change in T m 1 for A82F (59.6 °C) and an ~2 °C stabilization for the DM (59.9 °C). A similar effect was seen for F87V heme domain (T m = 63.1 °C) (Supplemental Data  Table S1 ). Thus, A82F has the major effect on stability of BM3, but F87V also destabilizes the protein and there is an additive effect on combining the mutations (Figure 10 , Supplemental Data Figure S5 , Table S1 ).
Discussion
The development of efficient biocatalysts that generate human drug metabolites has become an area of great interest. Human P450s are responsible for most phase I xenobiotic metabolism, producing numerous oxidized and other metabolites from human drugs (37) . For omeprazole, the principal metabolic pathway is 5-hydroxylation catalyzed by CYP2C19, the product of which can then be converted to the sulfone by CYP3A4. Oxidized metabolites of human drugs are required for pharmaceutical compliance, for metabolite safety testing, and for molecular interaction studies as required by FDA guidelines. Use of human P450s to produce small quantities of specific metabolites is a possibility, but caveats include slow reaction rates, requirement for a separate redox partner, and enzyme instability. Synthetic chemistry to make oxidized metabolites is an alternative, but controlling regioselectivity of oxidation, maintaining stability of compounds, and requirements for several steps giving low yield are major issues. An attractive alternative is to engineer high activity microbial P450s for specific oxidation of drugs.
A system of choice is P450 BM3, due to its catalytically self sufficient nature, high turnover rates and availability of excellent structural data to guide protein engineering. Crystal structures of substrate-free and fatty acid-bound forms of the wild-type BM3 heme domain drove early protein engineering studies on BM3 (7, 8) . This enabled identification of residues important in binding the substrate carboxylate at the mouth of the active site (Arg47 and Tyr51), as well as amino acids crucial for regulating heme iron redox potential (Phe393) and the coupling of electron transfer to substrate oxidation (Thr268) (6, (38) (39) (40) . Parallel studies documented its fast rates of fatty acid substrate oxidation, resulting from rapid electron transfer from NADPH through its fused cytochrome P450 reductase (CPR) partner (5, 41) , and more recent studies have confirmed that the enzyme is functional as a dimer (42, 43) , and that electron transfer to drive catalysis occurs between the CPR module of one monomer and the heme domain of the other in the BM3 dimer (44) .
The application of random mutagenesis, recombination and directed evolution approaches (pioneered by Frances Arnold's group) brought a new dimension to research on BM3, demonstrating that radical changes in its substrate selectivity could be engineered. A key development was the production of the 139-3 BM3 mutant (containing 11 mutations), which enabled the hydroxylation of a range of alkanes from octane through to propane, including cyclohexane (45) . However, only one mutation (V78A) occurred at a position known to be in contact with fatty acid from preceding structural data (8) . While mutations at Ala82 and Phe87 were not present in the 139-3 mutant, the addition of an A82L mutation to 139-3 resulted in increased coupling of NADPH oxidation to the hydroxylation of propane and octane, indicating improvements to the productive binding of these substrates. A related engineered BM3 variant (named 9/10A and containing 13 mutations, 8 of which are shared with 139-3) was inactive in ethane hydroxylation, but was shown to develop ethane hydroxylase activity and to improve propane hydroxylation when an A82S mutation was incorporated, together with either two or four further mutations (46) . A related propane hydroxylase variant (35E11) containing 16 mutations (mostly accumulated from the 139-3 and 9/10A progenitors) also has the A82S mutation, although propane hydroxylation rate and coupling were improved on introduction of further groups of mutations that included L188P (47) . The later structural data for the 139-3 mutant heme domain in complex with NPG provided insights into structural changes that could promote binding and oxidation of short chain alkanes, while retaining a conformational state (SB) similar to the WT-NPG complex structure (34) . In particular, active site mutation V78A enlarged a hydrophobic pocket close to the heme, while A184V enabled interactions with Leu437 across the active site channel, likely enabling van der Waals contacts with the terminal carbon of octane and protecting the substrate from solvent (48) . Predictive modelling based on the 139-3 structure indicated that A82S and other mutations altered substrate channel organization, but that the destabilizing L188P mutation was a major determinant in promoting efficient propane oxidation, and likely acted by inducing structural disruption at the end of the F-helix, favouring a conformational change towards a catalytically productive form (48) . Given the conservative nature of the A82S mutation, it is unclear whether this mutation alone might favour the SB conformation (as does the A82F mutation in our work). However, the SB structural conformation might be expected in any case for the NPG-bound enzyme.
The fact that the structurally destabilizing L188P mutation has profound effects on BM3 binding/turnover of propane has parallels in recent studies by Luet Wong's group -in which (i) a substrate-free I401P mutant (the mutated residue being adjacent to the heme proximal ligand Cys400) was crystallized in a SB-like conformation, and (ii) an A330P mutant in an inter-helical beta sheet part of the P450 caused structural disruption that reshaped the active site cavity. For both these mutants, large increases in catalytic activity with non-natural substrates such as toluene, propylbenzene and 3-methylpentane were observed (18, 49) .
While some structural data are available for BM3 variants promoting short chain/alkane binding and oxidation, there is also much interest in the application of BM3 mutants for the production of metabolites of human drugs. BM3 variants have been shown to oxidize drugs such as diclofenac, ibuprofen and acetaminophen, but no structural data were obtained (50, 51) . In this study, we present the first structure of a BM3 P450 bound to a human drug substrate (OMP), and show that a single active site mutation (A82F) is sufficient to facilitate tight binding of this PPI drug, enabling the same oxidative reaction (hydroxylation at the pyridinyl 5-methyl group) as catalyzed by the main human metabolizing P450 CYP2C19. OMP binding is further enhanced by introduction of the F87V mutation in the immediate vicinity of the heme, avoiding close contacts between Phe87 and the OMP. Despite the obvious differences between the natural fatty acid substrates and OMP, the conformation of the OMP-bound mutants is near identical to previously determined WT fatty acid complexes. This suggests BM3 active site architecture is largely determined by the overall protein conformation (SB vs. SF) rather than the exact nature of the ligand. Studies of human urinary metabolites of OMP showed that the 5-OH OMP and 5-COOH OMP were the major derivatives detected, with the former predominant (35, 52) . The relatively tight binding of the primary metabolite (5-OH OMP) to both A82F and (particularly) the DM BM3 reinforces that the oxidized derivative retains ability to bind in a catalytically competent mode to A82F-containing mutants, consistent with its further oxidation to 5-COOH OMP by the DM BM3 ( Figure 4 , Table 2 ). The BM3 DM's ability to catalyze successive OMP oxidations to generate 5-COOH OMP points to the possibility that CYP2C19 and/or other human CYPs might further oxidize 5-OH OMP to 5-COOH OMP.
Early structural studies of BM3's heme domain identified Phe87 as a key active site residue, mutations of which altered binding and regioselectivity of fatty acid oxidation (6, 10, 17) , and both Phe87 and Ala82 mutations are frequently contained in BM3 mutants generated by directed evolution and other strategies for altered substrate specificity (e.g. 13, 46) . Other studies on Phe87 mutants have further highlighted its importance in controlling access to the heme center and in altering reactivity. Notable recent studies have highlighted that an F87V BM3 mutant catalyzes hydroxylation of both testosterone and progesterone. In the case of testosterone, 2β-hydroxytestosterone and 16β-hydroxytestosterone were formed in roughly equal amounts by F87V BM3. However, triple mutants that also contained the A82F mutation (F87V, A82F, V78L/T/I) showed 3-4 fold greater catalytic efficiency and produced the 16β-hydroxytestosterone product at ~90%, suggesting an important influence of the A82F mutation on steroid binding mode (12) . Other work has pointed to the importance of Phe87 in tolerance to solvents used for substrate solubilization. Crystal structure data showed that DMSO was able to compete with the heme's 6 th ligand water molecule for coordination to the iron in the F87A heme domain mutant, but not in the WT heme domain at the same DMSO concentration (53) .
While the influence of Phe87 mutations on accessibility to the heme center is easily rationalized from crystal structure data, the mechanism by which Ala82 mutations diversify BM3 substrate selectivity has been relatively poorly understood. Huang et al. solved the crystal structure of a palmitate-bound A82F heme domain, after purifying the mutant from E. coli in the lipid-bound form (20) . The structure was similar to that of the NPG-bound WT heme domain (34) . Our studies of the substrate-free A82F structure reveal that the mutation induces a change in the protein conformational landscape, leading to a distinct and previously unobserved position of the FG helices. These structural changes have profound consequences for substrate binding in the A82F mutants, and point to a role for this residue as a "gatekeeper" for preferred substrate access as a consequence of its regulation of the conformational state and/or dynamics of structural change in the P450. Thus, although the mutation is removed from the immediate vicinity of the heme iron, it induces structural reconfiguration that enables the binding of OMP, and evidently that of other molecules. Our DSC studies show that the A82F mutation (in particular) alters the thermodynamic stability of BM3, decreasing the T m for protein unfolding. This suggests that its new conformational "flexibility" is a key facet underpinning its diversification of substrate selectivity, at least in part due to removal of inherent substrate bias towards long chain fatty acids by decreasing the free energy barrier corresponding to the transition to the SB-state ( Figure 10B ). These data are consistent with conclusions drawn by Bloom et al. with respect to the capacity of protein destabilizing mutations to impart novel substrate selectivity/reactivity on an enzyme (54).
In conclusion, our data point to new lessons to be learned from the outcomes of previous studies of BM3 (and other enzymes) in that amino acid changes that affect the dynamics of proteins in unpredictable ways may lead to mutations "distant" from the active site (or otherwise appearing not to impact significantly on substrate binding/affinity) having profound effects on enzyme catalysis and substrate specificity. The "gatekeeper" hypothesis thus points to Ala82 as a crucial target residue in research to enable further engineering of BM3 for diverse functions. Our findings show that, contrary to previous approaches focusing on increasing enzyme stability as a path to biotechnologically relevant enzymes (55, 56) . Also shown is the characteristic MS fragmentation position that gives the methoxybenzimidazole and 4-methoxy-3,5-dimethylpyridin-2-yl (pyridinyl) fragments. Hydroxylation on the 5-methyl group is performed by engineered variants of P450 BM3 described in this study. 5-hydroxylation is also the primary reaction catalyzed by the major human OMP-metabolizing enzyme CYP2C19. Omeprazole is chiral around the central sulfur atom. As a drug preparation, omeprazole is a racemate of two isomers. A direct hydrogen bond interaction is made between the backbone carbonyl of Leu437 and one of the OMP benzimidazole group nitrogens (NE1). A further bridging hydrogen bond occurs from the Ser72 hydroxyl group through a water molecule (water 781) to the other benzimidazole nitrogen (NV). A final bridging hydrogen bond interaction occurs between the backbone nitrogen of Ala74 and the benzimidazole methoxy oxygen (O3) via another water molecule (water 761). A number of hydrophobic protein-OMP interactions are seen. These include interactions with Leu188 at the benzimidazole methoxy group (C4), and with Ala328 at the pyridinyl 5-methyl group (C1). The diagram was produced using Ligplot+ using the structure of the A82F heme domain-omeprazole complex solved in this study (PDB code 4KEW) (58). A stereoview is shown for a structural overlay of the A82F BM3 heme domain with the WT heme domain (1BU7). Color coding is as in Figure 6 , with F/G helices in green for the substrate-free A82F mutant and in yellow for the substrate-free WT BM3 heme domain. 
